Immunization of healthy SIV-infected macaques with a formalin inactivated whole virus vaccine has no apparent effect on disease progression and survival.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Immunization of healthy SIV-infected macaques with a formalin inactivated whole virus vaccine has no apparent effect on disease progression and survival.

Symp Nonhum Primate Models AIDS. 1990 Nov 28-30;8:55 (abstract no. 39). Unique Identifier : AIDSLINE PRIM8/900039
Murphey-Corb M; Davison-Fairburn B; Ohkawa S; Martin L; Baskin G; Delta Regional Primate Research Center, Tulane University,; Covington, LA

Abstract: The association of the decline in HIV-specific antibody titers, specifically with respect to core determinants, to disease progression in infected humans, coupled with the relatively long latency between virus infection and the onset of disease, promotes the concept that immunization of healthy seropositive individuals may have a therapeutic effect. Since the SIV-infected macaque follows a similar fate, this model was utilized to evaluate the therapeutic efficacy of postinfection immunization with an inactivated whole virus vaccine. Three groups of 10 monkeys each were selected for their susceptibility to disease; half of each group was immunized with 100 ug whole virus + SAF-M; the remaining half were given 100 ug ovalbumin + SAF-M. All monkeys were inoculated with 10 I.D.50 SIV/DeltaB670 at time 0. Immunizations were initiated 2 weeks later at a time when virus infection was established but before signs of clinical disease, and continued at monthly intervals. Although increased antibody titers and glycoprotein-specific T-cell proliferative responses were detected in the whole virus vaccinates, no significant effect on T-cell subset changes and antigenemia were observed. Survival followed the pattern predicted for each group, but no significant difference between immunized and mock-immunized monkeys has been observed after 11 months of testing. These data suggest that postinfection immunotherapy using a vaccine found highly effective in preventing infection has little value in delaying disease progression and prolonging survival of the SIV-infected macaque.

Keywords: Animal Antibodies, Viral/IMMUNOLOGY Antigens, Viral/IMMUNOLOGY Disease Models, Animal Formaldehyde/*PHARMACOLOGY *Immunization Lymphocyte Transformation Macaca Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY SIV/DRUG EFFECTS/*IMMUNOLOGY T-Lymphocytes/MICROBIOLOGY Vaccines, Inactivated *Viral Vaccines Virus Activation/*DRUG EFFECTS ABSTRACT
910730
M9170955

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .